RxSight Statistics
Total Valuation
RxSight has a market cap or net worth of $1.36 billion. The enterprise value is $1.13 billion.
Important Dates
The last earnings date was Thursday, November 7, 2024, after market close.
| Earnings Date | Nov 7, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
RxSight has 40.30 million shares outstanding. The number of shares has increased by 16.36% in one year.
| Current Share Class | 40.30M |
| Shares Outstanding | 40.30M |
| Shares Change (YoY) | +16.36% |
| Shares Change (QoQ) | +3.47% |
| Owned by Insiders (%) | 4.95% |
| Owned by Institutions (%) | 74.71% |
| Float | 34.39M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 9.91 |
| Forward PS | 7.58 |
| PB Ratio | 4.89 |
| P/TBV Ratio | 4.89 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 8.81 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 12.67, with a Debt / Equity ratio of 0.04.
| Current Ratio | 12.67 |
| Quick Ratio | 11.60 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1,954.10 |
Financial Efficiency
Return on equity (ROE) is -13.99% and return on invested capital (ROIC) is -10.78%.
| Return on Equity (ROE) | -13.99% |
| Return on Assets (ROA) | -9.92% |
| Return on Capital (ROIC) | -10.78% |
| Revenue Per Employee | $343,029 |
| Profits Per Employee | -$82,070 |
| Employee Count | 374 |
| Asset Turnover | 0.52 |
| Inventory Turnover | 1.99 |
Taxes
In the past 12 months, RxSight has paid $20,000 in taxes.
| Income Tax | 20,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -13.76% in the last 52 weeks. The beta is 1.10, so RxSight's price volatility has been higher than the market average.
| Beta (5Y) | 1.10 |
| 52-Week Price Change | -13.76% |
| 50-Day Moving Average | 45.83 |
| 200-Day Moving Average | 51.50 |
| Relative Strength Index (RSI) | 26.98 |
| Average Volume (20 Days) | 840,937 |
Short Selling Information
The latest short interest is 2.58 million, so 6.41% of the outstanding shares have been sold short.
| Short Interest | 2.58M |
| Short Previous Month | 3.03M |
| Short % of Shares Out | 6.41% |
| Short % of Float | 7.51% |
| Short Ratio (days to cover) | 3.95 |
Income Statement
In the last 12 months, RxSight had revenue of $128.29 million and -$30.69 million in losses. Loss per share was -$0.81.
| Revenue | 128.29M |
| Gross Profit | 87.81M |
| Operating Income | -39.08M |
| Pretax Income | -36.75M |
| Net Income | -30.69M |
| EBITDA | -34.97M |
| EBIT | -39.08M |
| Loss Per Share | -$0.81 |
Full Income StatementBalance Sheet
The company has $237.12 million in cash and $11.30 million in debt, giving a net cash position of $225.82 million or $5.60 per share.
| Cash & Cash Equivalents | 237.12M |
| Total Debt | 11.30M |
| Net Cash | 225.82M |
| Net Cash Per Share | $5.60 |
| Equity (Book Value) | 277.26M |
| Book Value Per Share | 6.89 |
| Working Capital | 264.13M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$20.99 million and capital expenditures -$6.18 million, giving a free cash flow of -$27.17 million.
| Operating Cash Flow | -20.99M |
| Capital Expenditures | -6.18M |
| Free Cash Flow | -27.17M |
| FCF Per Share | -$0.67 |
Full Cash Flow StatementMargins
Gross margin is 68.44%, with operating and profit margins of -30.46% and -23.92%.
| Gross Margin | 68.44% |
| Operating Margin | -30.46% |
| Pretax Margin | -23.91% |
| Profit Margin | -23.92% |
| EBITDA Margin | -27.26% |
| EBIT Margin | -30.46% |
| FCF Margin | n/a |
Dividends & Yields
RxSight does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -16.36% |
| Shareholder Yield | -16.36% |
| Earnings Yield | -2.26% |
| FCF Yield | -2.00% |
Dividend DetailsAnalyst Forecast
The average price target for RxSight is $59.00, which is 75.28% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $59.00 |
| Price Target Difference | 75.28% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (5Y) | 28.05% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
RxSight has an Altman Z-Score of 30.02 and a Piotroski F-Score of 4.
| Altman Z-Score | 30.02 |
| Piotroski F-Score | 4 |